This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
TTP PLASMIC Score Calculator
Calculate the PLASMIC score for thrombotic thrombocytopenic purpura risk stratification. Enter seven readily available clinical and laboratory criteria to estimate the probability of severe ADAMTS13 deficiency (activity less than 10%) and guide urgent plasma exchange decisions in adults presenting with thrombotic microangiopathy.
| PLASMIC Score | Risk Category | ADAMTS13 Deficiency Probability | Recommended Action |
|---|---|---|---|
| 0 | Low | Less than 5% | Investigate alternative TMA. Send ADAMTS13 test. |
| 1 | Low | Less than 5% | Investigate alternative TMA. Send ADAMTS13 test. |
| 2 | Low | Less than 5% | Investigate alternative TMA. Send ADAMTS13 test. |
| 3 | Low | Less than 10% | Investigate alternative TMA. Send ADAMTS13 test. |
| 4 | Low | Less than 10% | Investigate alternative TMA. Send ADAMTS13 test. |
| 5 | Intermediate | Approximately 40-54% | Individualize plasma exchange. Hematology consult. |
| 6 | High | Greater than 72% | Urgent plasma exchange. Do not await ADAMTS13. |
| 7 | High | Greater than 72% | Urgent plasma exchange. Do not await ADAMTS13. |
Source: Bendapudi NM et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157-e164.
| Letter | Criterion | Threshold | Clinical Rationale |
|---|---|---|---|
| P | Platelet count | Less than 30 x 10^9/L | Severe thrombocytopenia from systemic platelet consumption in microvascular thrombi |
| L | Hemolysis (any one marker) | Retic greater than 2.5% OR haptoglobin undetectable OR indirect bili greater than 2 mg/dL | Confirms microangiopathic hemolysis; at least one marker sufficient |
| A | No active cancer | Malignancy absent | Active cancer causes non-ADAMTS13 TMA through endothelial damage and DIC |
| S | No transplant history | No stem cell or solid organ Tx | Transplant-associated TMA is calcineurin inhibitor and GVHD-mediated, not ADAMTS13-dependent |
| M | MCV | Less than 90 fL | Excludes macrocytic anemia from B12/folate deficiency complicating the TMA picture |
| I | INR | Less than 1.5 | Near-normal coagulation excludes DIC; iTTP causes platelet-rich not fibrin-rich thrombi |
| C | Creatinine | Less than 2.0 mg/dL (177 micromol/L) | Severe renal injury more typical of complement-mediated atypical HUS than iTTP |
| Maximum score | 7 points | Each criterion scores 1 point when the condition is met | |
| Diagnosis | Key Distinguishing Features | PLASMIC Score Tendency | Primary Treatment |
|---|---|---|---|
| Immune-mediated TTP (iTTP) | Severe thrombocytopenia, neurological symptoms, near-normal renal function, normal INR, ADAMTS13 less than 10% | High (6-7) | Plasma exchange, steroids, caplacizumab, rituximab |
| Atypical HUS (aHUS) | Severe acute kidney injury (creatinine often greater than 2 mg/dL), less severe thrombocytopenia, low C3, complement gene mutations | Low to intermediate | Eculizumab (anti-C5 antibody) |
| STEC-HUS | Diarrheal prodrome, Shiga toxin positive stool culture, primarily children, severe AKI | Low (usually) | Supportive – plasma exchange not indicated |
| DIC | Elevated INR, low fibrinogen, underlying trigger (sepsis, malignancy, trauma), consumptive coagulopathy | Low (INR elevated) | Treat underlying cause, replace factors |
| Drug-induced TMA | Drug exposure history (quinine, calcineurin inhibitors, VEGF inhibitors), may mimic iTTP clinically | Variable | Discontinue offending drug, supportive care |
| Malignancy-associated TMA | Active cancer present, bone marrow infiltration, leukoerythroblastic picture possible | Low (cancer present) | Treat underlying malignancy |
This table is a guide only. Clinical presentation, laboratory findings, and specialist consultation determine final diagnosis and management. Overlap between TMA syndromes is possible.
About This TTP PLASMIC Score Calculator
This TTP PLASMIC score calculator is designed for emergency physicians, hematologists, and hospitalists evaluating adults who present with suspected thrombotic microangiopathy (TMA). It computes the validated seven-point PLASMIC score to estimate the probability of severe ADAMTS13 deficiency – the biochemical hallmark of immune-mediated thrombotic thrombocytopenic purpura – using clinical and laboratory data available within the first hours of presentation. The PLASMIC criteria cover platelet count, hemolysis markers, absence of active cancer, absence of transplant history, MCV, INR, and creatinine.
The calculator implements the PLASMIC scoring system derived by Bendapudi and colleagues and published in The Lancet Haematology (2017), with subsequent external validation in European and North American cohorts. Each of the seven PLASMIC criteria contributes one point. Scores of 6-7 correspond to greater than 72% probability of ADAMTS13 activity below 10%, scores of 5 represent an intermediate range of 40-54%, and scores of 0-4 indicate less than 10% probability. The creatinine threshold of 2.0 mg/dL (177 micromol/L) and indirect bilirubin threshold of 2 mg/dL (34 micromol/L) are shown with conversion guidance for global use.
Clinicians can use this tool to make rapid, evidence-based triage decisions before ADAMTS13 results return from the reference laboratory – a window that typically spans 24-72 hours. The PLASMIC Severity Reference tab provides a score-by-score probability breakdown, the PLASMIC Clinical Criteria tab summarizes the rationale for each variable, and the TMA Differential Diagnosis tab maps the score to the broader differential. This calculator supports but does not replace expert hematology consultation, definitive ADAMTS13 testing, and comprehensive clinical assessment.
TTP Score Calculator - Complete Clinical Guide to Thrombotic Thrombocytopenic Purpura Risk Assessment
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy characterized by systemic platelet aggregation, microangiopathic hemolytic anemia, and end-organ ischemia. Rapid and accurate diagnosis is critical - untreated TTP carries a mortality rate exceeding 90%, yet with timely plasma exchange therapy, survival exceeds 80-90%. The PLASMIC score, a validated clinical prediction tool, enables clinicians to stratify patients by probability of severe ADAMTS13 deficiency (activity less than 10%), the defining biochemical abnormality in immune-mediated TTP. This TTP score calculator operationalizes the PLASMIC score to support urgent clinical decision-making in adults presenting with thrombotic microangiopathy.
What Is Thrombotic Thrombocytopenic Purpura (TTP)?
TTP is a thrombotic microangiopathy (TMA) defined by the combination of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and end-organ damage caused by microvascular platelet thrombi. The underlying mechanism involves severely reduced activity of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), the von Willebrand factor-cleaving protease. When ADAMTS13 activity falls below 10%, ultra-large von Willebrand factor multimers accumulate in the circulation, triggering spontaneous platelet aggregation and microvascular thrombosis throughout the body.
TTP has two principal forms. Immune-mediated TTP (iTTP), accounting for the vast majority of adult cases, results from autoantibodies - usually IgG - that inhibit or clear ADAMTS13. Hereditary TTP (Upshaw-Schulman syndrome) arises from biallelic ADAMTS13 gene mutations and is far less common. This calculator and the PLASMIC score pertain specifically to the diagnosis of acquired, immune-mediated ADAMTS13 deficiency in adults presenting with TMA.
Clinical Presentation and Diagnostic Challenge
The classic pentad of TTP - MAHA, thrombocytopenia, neurological symptoms, renal impairment, and fever - is present in fewer than 10% of patients at presentation. Most patients present with only two or three of these features, making clinical diagnosis challenging. The differential diagnosis of TMA is broad and includes hemolytic uremic syndrome (HUS), atypical HUS (complement-mediated), disseminated intravascular coagulation (DIC), malignant hypertension, HELLP syndrome (in pregnancy), drug-induced TMA, and catastrophic antiphospholipid syndrome.
Distinguishing TTP from other TMAs is clinically urgent because the treatment strategies differ substantially. Plasma exchange (PEX) with fresh frozen plasma is the cornerstone of iTTP treatment and must begin as rapidly as possible - ideally within hours of clinical suspicion. However, PEX is invasive and resource-intensive. Definitive ADAMTS13 testing requires specialized laboratory infrastructure and typically returns results in 24-72 hours, creating a diagnostic gap during which empirical treatment decisions must be made. This is precisely the context in which the PLASMIC score provides the greatest clinical value.
The PLASMIC Score - Development and Validation
The PLASMIC score was developed by Bendapudi and colleagues at Massachusetts General Hospital, published in The Lancet Haematology in 2017. The score was derived from a retrospective cohort of 214 adults presenting to a tertiary center with suspected TMA, and subsequently validated in an external cohort of 116 patients. The investigators identified seven readily available clinical and laboratory variables that together formed a robust prediction model for severe ADAMTS13 deficiency.
The acronym PLASMIC encodes the seven score components:
- Platelet count less than 30 x 10^9/L
- Lysis (combined hemolysis markers: reticulocyte count greater than 2.5% or haptoglobin undetectable or indirect bilirubin greater than 2 mg/dL)
- Absence of active cancer
- Stem cell or solid organ transplant - absence
- MCV less than 90 fL
- INR less than 1.5
- Creatinine less than 2.0 mg/dL (177 micromol/L)
Each variable contributes 1 point if present (or absent, as specified), yielding a total score of 0 to 7. Scores of 6-7 correspond to high probability of severe ADAMTS13 deficiency (greater than 72%), scores of 5 correspond to intermediate probability (approximately 40-54%), and scores of 0-4 correspond to low probability (less than 10%).
Detailed Breakdown of Each PLASMIC Criterion
Platelet Count Less Than 30 x 10^9/L (1 point): Severe thrombocytopenia is a hallmark of iTTP. The threshold of 30 x 10^9/L reflects the degree of platelet consumption seen in microvascular thrombosis. Platelet counts below this level suggest active systemic platelet aggregation rather than peripheral destruction from immune causes alone.
Hemolysis (1 point): This criterion captures microangiopathic hemolysis using three surrogate markers, with a positive score if any one of the following is present: reticulocyte count greater than 2.5% (reflecting the bone marrow's compensatory response to RBC destruction), haptoglobin undetectable (haptoglobin is consumed when free hemoglobin is released from lysed erythrocytes), or indirect bilirubin greater than 2 mg/dL (a product of heme catabolism). The requirement for at least one hemolysis marker helps confirm MAHA rather than isolated thrombocytopenia from other causes.
Absence of Active Cancer (1 point): Active malignancy is a major cause of TMA through several non-ADAMTS13 mechanisms including direct endothelial damage, DIC, and bone marrow infiltration. When cancer is present, TMA is far more likely to be cancer-associated rather than iTTP. A score of 1 is awarded when no active cancer is present.
No Stem Cell or Solid Organ Transplant History (1 point): Transplant recipients are at risk for several TMA syndromes including transplant-associated TMA (TA-TMA), calcineurin inhibitor toxicity, and graft-versus-host disease-associated TMA. These conditions are not typically ADAMTS13-mediated and are treated differently from iTTP. Absence of transplant history scores 1 point.
MCV Less Than 90 fL (1 point): A normal or low mean corpuscular volume suggests the patient does not have macrocytosis from nutritional deficiency or other causes that might mimic or complicate the TMA picture. More practically, the absence of macrocytosis strengthens the clinical coherence of an iTTP presentation.
INR Less Than 1.5 (1 point): The coagulation cascade is not primarily activated in iTTP, so PT/INR should be near-normal. An elevated INR suggests consumptive coagulopathy (as in DIC), liver disease, or anticoagulant use - all of which point away from iTTP as the primary diagnosis. A near-normal INR (below 1.5) scores 1 point and supports the diagnosis of iTTP.
Creatinine Less Than 2.0 mg/dL (1 point): Moderate renal impairment is more characteristic of atypical HUS (complement-mediated TMA) than iTTP. While mild renal involvement occurs in iTTP, severe renal impairment (creatinine greater than or equal to 2.0 mg/dL or 177 micromol/L) raises the likelihood of complement-mediated TMA. A creatinine below the threshold scores 1 point.
Score Interpretation and Clinical Thresholds
Score 5: INTERMEDIATE RISK - Approximately 40-54% probability
Score 6-7: HIGH RISK - Greater than 72% probability
Low Risk (Score 0-4): Severe ADAMTS13 deficiency is unlikely. Clinicians should investigate alternative diagnoses including atypical HUS (consider complement evaluation and anti-complement therapy), thrombotic microangiopathy from other causes, and drug-induced TMA. Empirical plasma exchange for iTTP is generally not warranted unless clinical deterioration occurs or the clinical picture evolves. ADAMTS13 testing should still be sent to confirm.
Intermediate Risk (Score 5): This is the most clinically challenging category. Approximately 40-54% of patients in this group have severe ADAMTS13 deficiency. The decision to initiate plasma exchange should be individualized, weighing clinical severity, organ involvement (particularly neurological symptoms), and the feasibility of rapid ADAMTS13 testing. Many experienced centers will initiate PEX in intermediate-risk patients with neurological involvement or severe thrombocytopenia.
High Risk (Score 6-7): Severe ADAMTS13 deficiency is very likely. Urgent plasma exchange should be initiated without waiting for ADAMTS13 results. The original validation data showed that greater than 72% of patients in this category had ADAMTS13 activity less than 10%. In centers where caplacizumab is available, anti-VWF therapy can be considered as an adjunct to PEX and immunosuppression.
Treatment Approach Based on PLASMIC Score
Understanding the treatment implications of each risk category is essential for translating the PLASMIC score into clinical action.
Plasma Exchange (PEX): The definitive treatment for iTTP removes inhibitory antibodies and replaces ADAMTS13. Initiated as large-volume (1-1.5 plasma volumes per session) exchanges using fresh frozen plasma or solvent-detergent plasma, PEX should begin as rapidly as possible in high-risk patients. Each hour of delay in initiating PEX corresponds to additional microvascular thrombotic injury. Treatment continues daily until platelet count recovery (greater than 150 x 10^9/L for at least two consecutive days), typically requiring 7-14 sessions.
Corticosteroids: High-dose corticosteroids (prednisolone 1 mg/kg/day or methylprednisolone 1 g/day for three days) are routinely added to suppress the autoimmune response driving ADAMTS13 inhibitor production. Corticosteroids are generally started concurrently with PEX in confirmed or highly suspected iTTP.
Caplacizumab: This anti-VWF nanobody blocks the interaction between VWF and platelet glycoprotein Ib, preventing ongoing platelet aggregation regardless of ADAMTS13 activity. Phase III trial data (HERCULES trial) demonstrated that caplacizumab significantly reduces time to platelet response, TTP-related deaths, and recurrence. Caplacizumab is now included in guidelines from the International Society on Thrombosis and Haemostasis (ISTH) as part of frontline treatment for iTTP.
Rituximab: This anti-CD20 monoclonal antibody depletes B-cells and reduces autoantibody production. Used upfront in severe or refractory cases, rituximab reduces relapse rates and ADAMTS13 inhibitor levels. Some centers use rituximab routinely in all newly diagnosed iTTP patients to prevent relapse.
Validation Studies and Score Performance
The PLASMIC score has been validated in multiple independent cohorts across diverse clinical settings worldwide. The 2017 original validation cohort by Bendapudi demonstrated an area under the receiver operating characteristic curve (AUC-ROC) of 0.96 in the derivation set and 0.93 in the validation set, reflecting excellent discriminative performance.
Subsequent validation studies have confirmed its utility in European, Asian, and multicenter North American cohorts. A 2019 study by Knoebl and colleagues in a European cohort (n=196) found broadly consistent performance, with high-risk scores predicting ADAMTS13 deficiency with a positive predictive value of approximately 75%. A 2021 multicenter retrospective analysis across multiple academic medical centers confirmed that low PLASMIC scores effectively identified patients unlikely to have iTTP, supporting its use as a tool to avoid unnecessary PEX in low-risk patients.
Some validation studies have noted modestly lower specificity in certain populations, particularly when patients with atypical HUS or other complement-mediated TMAs were included. The score performs best when applied to adult patients presenting with undifferentiated TMA in the absence of pregnancy (where TTP-like presentations require separate consideration).
The PLASMIC score was derived and validated primarily in adult, non-pregnant patients presenting with TMA at tertiary medical centers. It should not be applied to children, pregnant patients (particularly those with HELLP syndrome), or patients with established alternative diagnoses. The score supports - but does not replace - comprehensive clinical evaluation and expert hematology consultation.
ADAMTS13 Testing - The Definitive Investigation
ADAMTS13 activity measurement is the definitive biochemical test for iTTP diagnosis. Activity less than 10% confirms severe deficiency consistent with iTTP, while the presence of an ADAMTS13 inhibitor (detected by the Bethesda inhibitor assay) confirms the immune-mediated etiology. Anti-ADAMTS13 IgG antibody levels can be measured by ELISA and provide additional diagnostic and prognostic information.
The practical limitation of ADAMTS13 testing is turnaround time. Most hospital laboratories send ADAMTS13 assays to reference laboratories, with results returning in 24-72 hours. During this window, the PLASMIC score fills a critical diagnostic gap by providing an evidence-based probability estimate to guide empirical treatment decisions. Once ADAMTS13 results are available, they supersede the PLASMIC score for ongoing management decisions.
ADAMTS13 activity should also be monitored during and after treatment. Recovery of ADAMTS13 activity (greater than 10%, and ideally greater than 20-30%) correlates with clinical response and guides treatment duration. Persistent severe deficiency despite clinical improvement may indicate ongoing antibody production and can predict early relapse.
Differential Diagnosis of Thrombotic Microangiopathy
The differential diagnosis of TMA is broad, and clinical features that suggest alternative diagnoses should prompt reconsideration even when the PLASMIC score is high.
Atypical HUS (aHUS): Complement-mediated TMA typically presents with more severe renal impairment (creatinine often greater than 2 mg/dL), less severe thrombocytopenia, and the absence of neurological symptoms at presentation. The C3 level may be low. Genetic testing for complement gene mutations and anti-complement factor H antibodies supports the diagnosis. Eculizumab (anti-C5 monoclonal antibody) is the treatment of choice for aHUS and should not be delayed if aHUS is suspected.
DIC: Disseminated intravascular coagulation presents with coagulopathy (elevated PT/INR, aPTT, low fibrinogen) in addition to thrombocytopenia and hemolysis. The INR criterion in the PLASMIC score (less than 1.5 scores 1 point) directly addresses this distinction. DIC is typically associated with an underlying trigger such as sepsis, malignancy, or trauma.
Shiga toxin-mediated HUS (STEC-HUS): Primarily affects children following diarrheal illness caused by Shiga toxin-producing Escherichia coli (STEC O157:H7 and others). Stool culture, Shiga toxin assays, and serotyping confirm the diagnosis. Plasma exchange is not indicated and may be harmful in STEC-HUS.
Drug-induced TMA: Multiple drugs can cause TMA through immune or toxic mechanisms. Quinine, calcineurin inhibitors, VEGF pathway inhibitors, and certain chemotherapy agents are well-recognized causes. Drug history is an essential part of TMA evaluation.
Monitoring and Relapse Assessment
iTTP has a relapse rate of approximately 30-50% over a patient's lifetime. ADAMTS13 activity monitoring after achieving remission (typically 6-monthly) can identify subclinical recurrence before clinical relapse. Persistently low ADAMTS13 activity (less than 10%) in clinical remission or rising ADAMTS13 inhibitor titers are associated with impending relapse and may prompt preemptive rituximab therapy.
Patients should be educated about symptoms of relapse - including petechiae, bruising, dark urine, and neurological symptoms - and instructed to seek emergency evaluation promptly. Carrying a medical alert card identifying their diagnosis facilitates rapid assessment in emergency settings.
TTP is a hematological emergency. In any patient with unexplained thrombocytopenia and hemolytic anemia, TTP must be considered immediately. The PLASMIC score should be calculated at presentation. High-risk scores (6-7) warrant emergent hematology consultation and plasma exchange initiation within hours, not days. Time to plasma exchange is directly associated with patient outcomes.
Special Populations and Considerations
Pregnancy-Associated TMA: TMA presenting during pregnancy or the postpartum period requires separate clinical algorithms. TTP, HELLP syndrome, preeclampsia, atypical HUS, and acute fatty liver of pregnancy can all cause TMA in this context. The PLASMIC score has not been formally validated in pregnant patients, and obstetric input alongside hematology consultation is essential.
HIV-Associated TTP: Patients with HIV infection have an increased risk of iTTP, possibly due to endothelial dysfunction, immunological dysregulation, and drug effects. The PLASMIC score can be applied in this population, but antiretroviral drug-induced TMA must also be considered in the differential.
Pediatric TTP: The PLASMIC score was validated in adults. In children presenting with TMA, Shiga toxin-mediated HUS is far more common than iTTP. Hereditary TTP (Upshaw-Schulman syndrome) should be considered in pediatric TMA, particularly with a history of neonatal jaundice or recurrent TMA. Pediatric hematology consultation is essential.
Recurrent TTP: Patients with known iTTP presenting with relapse may have a different risk profile than those with first-episode presentation. Previous treatment history, ADAMTS13 inhibitor status, and prior response to therapy should inform management alongside PLASMIC score calculation.
Global Application and Population Considerations
The PLASMIC score was derived from a predominantly North American patient population. Its performance has been validated in European and some Asian cohorts, and the score appears to perform consistently across these populations for its core purpose of predicting severe ADAMTS13 deficiency. The biological mechanisms underlying iTTP - autoantibody-mediated ADAMTS13 deficiency - are not population-specific, and the laboratory parameters used in the PLASMIC score are universally available.
Some studies have suggested modest differences in ADAMTS13 antibody prevalence across ethnic groups, and the absolute incidence of iTTP varies geographically (approximately 2-13 cases per million population per year in high-income settings). However, these epidemiological variations do not materially affect the use of the PLASMIC score as a within-patient probability estimator once TMA has been identified clinically.
Units for creatinine differ by region (mg/dL in North America versus micromol/L in Europe and many other settings). The threshold of 2.0 mg/dL is equivalent to 177 micromol/L. This calculator accepts both units to accommodate global users. Similarly, bilirubin may be reported in mg/dL or micromol/L, with 2 mg/dL equivalent to approximately 34 micromol/L.
Integration with Clinical Workflows
The PLASMIC score is most useful as part of a structured TMA evaluation pathway. The following framework integrates the score into clinical decision-making:
Step 1 - Confirm TMA: Establish the presence of MAHA (schistocytes on blood film, elevated LDH, low haptoglobin) and thrombocytopenia. Consider peripheral blood smear review as an early priority.
Step 2 - Send urgent investigations: Complete blood count, reticulocyte count, peripheral blood film, LDH, haptoglobin, indirect bilirubin, coagulation screen (PT, INR, aPTT, fibrinogen), renal function, liver function, ADAMTS13 activity and inhibitor (urgent), direct antiglobulin test, blood group and screen, STEC serology/stool culture (if diarrheal prodrome), complement levels (C3, C4, CH50), anti-complement factor H antibodies, and HIV serology.
Step 3 - Calculate PLASMIC Score: Using the results available at presentation (may require re-calculation as laboratory values return).
Step 4 - Initiate treatment according to risk stratification: High-risk patients (score 6-7) should proceed to plasma exchange immediately. Intermediate-risk patients (score 5) require individualized assessment. Low-risk patients (score 0-4) should be evaluated for alternative TMA diagnoses.
Step 5 - Monitor and adjust: Daily clinical assessment, platelet count, LDH. Adjust treatment as ADAMTS13 results return and clinical response is observed.
Frequently Asked Questions
Conclusion
The PLASMIC score is a validated, rapidly applicable clinical prediction tool that stratifies adults presenting with thrombotic microangiopathy by probability of severe ADAMTS13 deficiency - the biochemical signature of immune-mediated TTP. Its seven criteria use universally available clinical and laboratory data, enabling evidence-based triage decisions within hours of presentation, before definitive ADAMTS13 results are available.
High-risk scores (6-7) should prompt urgent plasma exchange initiation, hematology consultation, and consideration of caplacizumab. Intermediate-risk scores (5) require individualized clinical assessment. Low-risk scores (0-4) direct clinicians toward alternative TMA diagnoses, particularly complement-mediated atypical HUS. The score does not replace ADAMTS13 testing, clinical expertise, or hematology consultation - it augments the initial assessment framework in a time-critical clinical emergency.
This calculator is provided for educational and clinical reference purposes. Healthcare providers should always integrate the PLASMIC score with comprehensive clinical assessment, expert consultation, and institutional protocols. TTP remains a hematological emergency in which rapid, coordinated action across emergency medicine, hematology, and transfusion medicine services determines patient outcomes.
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.